Peripheral Arterial Disease - Pipeline Insight, 2024

This “Peripheral Arterial Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peripheral Arterial Disease Understanding

Peripheral Arterial Disease: Overview

Peripheral arterial disease (PAD) is a circulatory problem causing a reduced blood flow through the arteries. This typically reduces blood flow to the extremities manifesting as thigh or calf pain during walking or exertion. Patients with peripheral arterial disease (PAD) have decreased lower extremity arterial perfusion which is commonly referred to as “poor circulation.” In most cases of PAD, atherosclerotic plaques narrow the arterial flow lumen which restricts blood flow to the distal extremity. Reduced blood flow can cause thigh or calf pain with walking due to temporary ischemia of the leg muscles during exertion. PAD affects over 200 million adults worldwide and the incidence of PAD increases to as high as 20% in people over the age of 70. Making the diagnosis of PAD should factor in the patient’s history, physical exam, and objective test results. Blood work may reveal altered renal function and abnormal electrolyte levels. Elevation in CRP, D-dimer and interleukin 6 have been associated with diminished exercise tolerance. Management strategies for PAD attempt to achieve two distinct goals: lower cardiovascular risk and improve walking ability. Once the diagnosis of PVD is made, lifelong follow up is required. The disorder has no cure and if the lifestyle is not modified, the condition progresses.

Peripheral Arterial Disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease treatment guidelines. The assessment part of the report embraces, in depth Peripheral Arterial Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease.

Peripheral Arterial Disease Emerging Drugs Chapters

This segment of the Peripheral Arterial Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral Arterial Disease Emerging Drugs

Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently in Phase III stage of development for the treatment of patients with Type 2Diabetes Mellitus, and Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease(PVD).

VM202: Helixmith Engensis (VM202) is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith’s non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. Engensis (VM202) has the potential to promote blood vessel formation in the ischemic area by HGF-based angiogenesis. In addition, the HGF-based angiogenesis may also contribute to cardiac muscle function improvement through the suppression of apoptosis and cardiacfibrosis.

Peripheral Arterial Disease: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral Arterial Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral Arterial Disease

There are approx. 18+ key companies which are developing the therapies for Peripheral Arterial Disease. The companies which have their Peripheral Arterial Disease drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.

Phases

This report covers around 18+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Arterial Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease drugs.

Peripheral Arterial Disease Report Insights

• Peripheral Arterial Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral Arterial Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral Arterial Disease drugs?
• How many Peripheral Arterial Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peripheral Arterial Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.